Xponance Inc. Has $30.33 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Xponance Inc. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,362 shares of the medical research company’s stock after selling 2,346 shares during the period. Xponance Inc.’s holdings in Amgen were worth $30,329,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new stake in Amgen during the 4th quarter worth about $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen during the 3rd quarter worth approximately $29,000. Synergy Investment Management LLC bought a new stake in Amgen during the 4th quarter worth approximately $34,000. Atala Financial Inc bought a new stake in Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC acquired a new position in Amgen during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.1 %

Shares of AMGN stock opened at $317.17 on Tuesday. The company has a market cap of $170.39 billion, a P/E ratio of 42.01, a PEG ratio of 2.63 and a beta of 0.53. The stock has a 50 day simple moving average of $292.99 and a two-hundred day simple moving average of $299.02. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.00%. Amgen’s dividend payout ratio is 126.09%.

Insider Activity

In related news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 over the last quarter. 0.69% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent analyst reports. Citigroup reissued a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Piper Sandler increased their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, UBS Group reiterated a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.